About Novartis (NYSE:NVS)
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio15.76
Forward P/E Ratio14.46
Sales & Book Value
Annual Sales$49.11 billion
Price / Sales3.58
Cash Flow$7.5338 per share
Price / Cash10.06
Book Value$32.03 per share
Price / Book2.37
EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Return on Equity16.23%
Return on Assets8.69%
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How will Novartis' stock buyback program work?
Novartis announced that its board has approved a stock buyback program on Saturday, April 8th 2017, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) released its quarterly earnings data on Thursday, April, 19th. The company reported $1.28 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.25 by $0.03. The firm had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.45 billion. Novartis had a return on equity of 16.23% and a net margin of 16.04%. Novartis's revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.13 EPS. View Novartis' Earnings History.
When is Novartis' next earnings date?
What price target have analysts set for NVS?
11 equities research analysts have issued 12-month price targets for Novartis' stock. Their predictions range from $82.25 to $91.00. On average, they anticipate Novartis' share price to reach $87.75 in the next twelve months. View Analyst Ratings for Novartis.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
- Mr. Harry Kirsch, Chief Financial Officer (Age 53)
- Mr. Steven Baert, Head of HR (Age 44)
- Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)
- Mr. F. Michael Ball, CEO, Alcon (Age 63)
Has Novartis been receiving favorable news coverage?
Headlines about NVS stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novartis earned a media sentiment score of 0.14 on Accern's scale. They also gave news stories about the company an impact score of 47.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Novartis' major shareholders?
Novartis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (0.64%), Loomis Sayles & Co. L P (0.34%), Fisher Asset Management LLC (0.30%), Northern Trust Corp (0.18%), Thomaspartners Inc. (0.17%) and BlackRock Inc. (0.17%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.
Which institutional investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., The Manufacturers Life Insurance Company, Reynders McVeigh Capital Management LLC, BlackRock Inc., Manning & Napier Group LLC, Federated Investors Inc. PA, Blair William & Co. IL and Senzar Asset Management LLC. View Insider Buying and Selling for Novartis.
Which institutional investors are buying Novartis stock?
NVS stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Rockefeller Capital Management L.P., Loomis Sayles & Co. L P, Boston Partners, Millennium Management LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC and Sei Investments Co.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $75.79.
How big of a company is Novartis?
Novartis has a market capitalization of $175.64 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NVS)MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.